Peptides DB
Research-centric peptide and protocol reference hub

Vosoritide record · updated 6h ago

Healing & recoveryMuscle & body compGrade A · human clinicalResearch use only
All 27 studiesJump to the evidenceCompare
What is Vosoritide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: Natriuretic peptide receptor 2 agonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where Vosoritide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 19 registered trials. It describes the research record, not a recommendation.

Identity
NameVosoritide
Chain length—
Molecular weight4,103 Da
FormulaC176H290N56O51S3
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 119058036. No verified residue count for this compound.

Pharmacology
MechanismNatriuretic peptide receptor 2 agonist
RouteSubcutaneous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 19, 2026. How this works →
Research stats
Total studies27
Human / animal / cellular15 / 4 / 1
Highest trial phasePhase 3
Years covered2018–2026
Latest study2d ago
Publication history
20182026
Research funding
—no NIH grants found
Safety signals
FAERS reports3
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

27 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
A Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia.
Finding0.24 mg vosoritide administered, equivalent to 53 μg/kg.
Human2026Full text read0.80
A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.
FindingLSM difference of 2.33 cm/year between vosoritide and placebo; 95% CI, 1.85-2.82 cm/year; two-sided P<0.0001.
Human2023Full text read0.90
A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.
FindingLSM difference of 2.33 cm/year between vosoritide and placebo, 95% CI 1.85-2.82 cm/year, two-sided P<0.0001.
Human2023Full text read0.90
Perceived Impact of Vosoritide on Health-Related Quality of Life in Children with Selected Genetic Causes of Short Stature: A Qualitative Study of Children and Caregivers.
Finding74% of caregivers and 100% of children reported changes in daily activities.
Human2026Full text read0.70
From Small Data to Big Decisions: How Clinical Pharmacology Shapes Rare Disease Development.
TakeawayClinical pharmacology's integration of diverse data sources supports rare-disease drug development by informing key regulatory decisions.
review2026Full text read0.80
Slipped Capital Femoral Epiphysis during Vosoritide Therapy for Short Stature: A Case Series.
Finding2/12 participants with ACAN mutations developed SCFE.
Human2023Full text read0.80
Real-World Evidence on the Effectiveness and Safety of Vosoritide in Latin American Patients With Achondroplasia (EVOLAC).
FindingHeight Z-scores increased from 0.33 to 1.58 between 6 to 36 months, p<0.001 to p<0.05.
Human2023Full text read0.80
From FGFR3 Hyperactivation to Disease-Modifying Therapy in Pediatric Achondroplasia: Molecular Mechanisms, Clinical Evidence, and Emerging Treatments.
FindingNot reported in abstract.
review2023Full text read0.70
Healthcare and Psychosocial Needs in Achondroplasia Across the Lifespan: Developmental Functioning, Multidisciplinary Care, and Family-Centered Outcomes.
FindingNot reported in abstract.
review2026Full text read0.70
C-type natriuretic peptide analog treatment of craniosynostosis in a Crouzon syndrome mouse model.
FindingNot reported in abstract.
Animal2018Full text read0.80
Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth.
FindingNot reported in abstract.
Animal2021Full text read0.70
Guanylyl Cyclase-B Dependent Bone Formation in Mice is Associated with Youth, Increased Osteoblasts, and Decreased Osteoclasts.
FindingSclerostin mRNA was elevated 400-fold.
Animal2022Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Vosoritide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Vosoritide is discussed should be drawn from it.